Reflow Medical Expands Global Reach With New European Subsidiary

Reflow Medical Inc. has opened a European subsidiary in Landsberg am Lech, Germany in a strategic move designed to strengthen the company’s international presence and improve its ability to serve markets outside the United States.

“Expanding into markets outside the United States marks a significant milestone for our company,” Reflow Medical Co-Founder/CEO Isa Rizk said. “This presence allows us to better address the needs of international markets by providing direct sales solutions and forming key distribution collaborations. Our goal is to deliver breakthrough technologies that support physicians and improve patient outcomes worldwide.”

Reflow Medical Co-Founder/Chief Operating Officer John Fulkerson emphasized the new base’s operational benefits. “This expansion enables us to streamline product distribution, significantly reducing delivery times and enhancing service reliability,” he explained. “These factors are critical to maintaining high quality standards in the medical device industry.”

Reflow Medical Europe GmbH is led by Senior Vice President/General Manager Knut Sauerteig, who will focus on establishing direct sales channels and forging strategic distribution partnerships across multiple regions.

“Our team is committed to driving growth across Europe, the Middle East, Africa, Latin America, and the Asia-Pacific region,” Sauerteig stated. “In the coming years, we will continue to expand our presence by building direct sales organizations and strengthening distribution partnerships to better serve the needs of healthcare providers and patients.”

The launch of Reflow Medical Europe GmbH underscores the company’s dedication to advancing cardiovascular care on a global scale.

San Clemente, Calif.-based Reflow Medical is a global company working with physicians to develop technologies designed to fill unmet clinical needs in complex cardiovascular disease treatment. The firm’s portfolio consists of the CoraCatheters line of coronary microcatheters to cross complex lesions (available in the United States only) as well as peripheral catheters, including the Wingman CTO Crossing Catheter, the Spex and Spex LP Shapeable Support Microcatheters, and the Spur Peripheral Retrievable Scaffold System. The Spur has earned the CE Mark to treat restenotic lesions in below-the-knee arteries, when used in conjunction with a commercially available drug-coated balloon. The Spur is an investigational device in the United States.